EODData

MEMBERSHIP REGISTER LOG IN

FRA, 36X: ASCENTAGE PHARM. DL-0001

03 Sep 2025
LAST:

8.800

CHANGE:
 0.15		OPEN:
8.800		HIGH:
8.850		ASK:
0.000		VOLUME:
3K
CHG(%):
1.73		PREV:
8.650		LOW:
8.800		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
03 Sep 258.8008.8508.8008.8003K
02 Sep 258.6508.6508.6508.6500
01 Sep 259.0509.1008.6508.6503K
29 Aug 259.1009.1009.1009.1003K
28 Aug 258.8508.8508.8508.8503K
27 Aug 258.8008.8508.6508.6503K
26 Aug 259.4009.4009.4009.4000
25 Aug 259.3509.4009.3509.4003.9K
22 Aug 2510.00010.0009.9009.9003.9K
21 Aug 259.7509.8509.7509.8503.9K

COMPANY PROFILE

Name:ASCENTAGE PHARM. DL-0001
About:Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, an orally available and selective embryonic ectoderm development inhibitor. In addition, it is involved in medical research and development; clinical development; clinical trials operations; venture capital investment; rental of buildings; and provision of science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.
Sector:Healthcare
Industry:Biotechnology
Address:Suzhou Industrial Park, Suzhou, China, 215000
Website:https://www.ascentage.cn
ISIN:KYG0519B1023

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:8.81
MA10:9.13
MA20:9.14
MA50:8.69
MA100:7.25
MA200:5.92
STO9:11.11
STO14:11.11
RSI14:47.95
WPR14:-88.00
MTM14:-0.55
ROC14:-0.06
ATR:0.29
Week High:9.10
Week Low:8.65
Month High:10.00
Month Low:8.00
Year High:10.00
Year Low:3.61
Volatility:20.46